134653-98-8

Usage

Uses

Used in Pharmaceutical Research and Development:
Ethyl 6-(tert-butyl)-4-oxo-1,4-dihydropyridine-3-carboxylate is utilized as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a promising candidate for drug discovery, potentially leading to the development of new therapeutic agents.
Used in Drug Discovery:
In the field of drug discovery, Ethyl 6-(tert-butyl)-4-oxo-1,4-dihydropyridine-3-carboxylate serves as a key component in the design and synthesis of novel drug molecules. Its presence in the molecular structure can influence the pharmacokinetic and pharmacodynamic properties of the resulting compounds, enhancing their therapeutic potential.
Used in Medicinal Chemistry:
Ethyl 6-(tert-butyl)-4-oxo-1,4-dihydropyridine-3-carboxylate is employed as a building block in medicinal chemistry for the creation of new chemical entities. Its versatile structure allows for modifications and functionalization, enabling the development of compounds with improved biological activity and selectivity.
Used in Drug Synthesis:
In the synthesis of pharmaceuticals, Ethyl 6-(tert-butyl)-4-oxo-1,4-dihydropyridine-3-carboxylate acts as a precursor or a reactant in various chemical reactions. Its reactivity and compatibility with other molecules facilitate the production of diverse drug candidates with potential therapeutic applications.
Note: The specific applications mentioned above are hypothetical and based on the general properties of the compound. Further research and testing would be required to confirm the exact uses and potential of Ethyl 6-(tert-butyl)-4-oxo-1,4-dihydropyridine-3-carboxylate in various industries.

Upstream product

• 134653-70-6 ethyl 2-[(dimethylamino)methylene]-3-oxobutanoate 
• 1538-75-6 2,2-dimethylpropanoic anhydride 
• 134653-81-9 ethyl 6-tert-butyl-4-oxo-4H-pyran-3-carboxylate 

Downstream Products

• 1143522-26-2 2-{1-[(4S,5R)-2-(6-tert-butyl-4-ethoxy-pyridin-3-yl)-4,5-bis-(4-chloro-phenyl)-4,5-dimethyl-4,5-dihydro-imidazole-1-carbonyl]-piperidin-4-yl}-acetamide 
• 1143519-25-8 rac-[(4S,5R)-2-(6-tert-butyl-4-ethoxy-pyridin-3-yl)-4,5-bis-(4-chloro-phenyl)-4,5-dimethyl-4,5-dihydro-imidazol-1-yl]-[4-(3-methanesulfonyl-propyl)-piperazin-1-yl]-methanone 
• 1143519-21-4 6-tert-butyl-4-ethoxy-nicotinic acid 

Relevant academic research and scientific papers

Efficient large-scale synthesis of a 2,4,5-triarylimidazoline MDM2 antagonist

An improved, kilogram-scale synthesis of a triarylimidazoline MDM2 antagonist is reported. The nicotinic acid component was prepared in three steps from ethyl 2-dimethylaminomethylene-3-oxo-butyrate. The coupling of the nicotinic acid with the meso-diamine selectively produced the monoamide which was cyclized in the presence of p-TSA/pyridine to give the imidazoline core. Phosgenation using bis(trichloromethyl) carbonate provided the key carbamoyl chloride intermediate, which was coupled with the side-chain amine, followed by chiral resolution with (R)-camphorsulfonic acid to give the final API.

CHIRAL CIS-IMIDAZOLINES

There are provided compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein X, Y, Z, V1, V2, R1, R2, R3, R4 and R5 are as herein described, processes for obtaining said compounds and pharmaceutical preparations containing them. These compounds are useful as anticancer agents, in particular as agents in the treatment of solid tumors.